Exhibit 99.1 Condensed consolidated income statement (unaudited) | --- | --- | --- | --- | --- | |---------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|------------------------------------------------------|--------------------------------------------------| | £000s (except per share information) | Three months ended \nJune 30, 2024 \n£000s | Three months ended \nJune 30, 2023 \n£000s | Six ...

Last month, the company announced positive data from the ongoing phase I repeat dose SANRECO study on its pipeline candidate, divesiran (SLN124) for treating patients with polycythemia vera. Treatment with divesiran was generally well-tolerated and eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing. This might have driven the share price rally. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) s ...

Risks To Business A third risk to consider would be regarding the partnership with AstraZeneca that had been done to advance siRNA drug candidate for the treatment of patients with cardiovascular, renal, metabolic and respiratory diseases. Thus far, Silence Therapeutics was able to receive $10 million from the collaboration agreement because of the nomination of one candidate. The ability to obtain additional milestone payments is going to depend upon whether other candidates are ultimately nominated. There ...

Silence Therapeutics plc (NASDAQ:SLN) Q4 2023 Earnings Conference March 13, 2024 8:00 AM ET Company Participants Gem Hopkins - Head of Investor Relations & Corporate Communications Craig Tooman - President & Chief Executive Officer Rhonda Hellums - Chief Financial Officer Steven Romano - Head of R&D Conference Call Participants Mike Ulz - Morgan Stanley Kostas Biliouris - BMO Capital Markets Patrick Trucchio - H.C. Wainwright Keay Nakae - Chardan Research Operator Good day, and thank you for standing by. We ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Full Year 2023 Conference Call March 13, 2024 Forward-Looking Statements 2 The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any such ...

Exhibit 99.1 Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a) The 60-week study is ongoing and secondary endpoints, including change in Lp(a) from baseline to 48 weeks (end of treatment period), 60 weeks (end of study) and potential effects on other lipids/lipoproteins, will be evaluated. "We are excited about the emerging phase 2 data, which are very consistent with phase 1 results and support a competitive profile fo ...

Financial Data and Key Metrics Changes - The company's net loss for the full year 2022 was £40.5 million compared to a net loss of £39.4 million in 2021, reflecting an increase in R&D expenses due to advancing clinical programs [17] - Revenue for the year ended December 31, 2022, was £17.5 million, up from £12.4 million in 2021, driven by advancements in partnered programs [28] - Cash and cash equivalents were £71.1 million (approximately US$86 million) at the end of December 2022, with an estimated cash runway through the first quarter of 2024 [17][50] Business Line Data and Key Metrics Changes - The SLN360 program, now known as Zerlasiran, reported up to 98% efficacy in the APOLLO study, with strong durability after a single dose [25] - The SLN124 program is progressing in the clinic, with encouraging preliminary safety results reported in the GEMINI II Phase I thalassemia study [14][21] Market Data and Key Metrics Changes - Elevated Lp(a) levels are recognized to affect up to 1.4 billion people worldwide, representing a significant unaddressed health issue [31] - The company is focusing on a target population with Lp(a) levels greater than or equal to 125 nmol per liter for the Phase II study, which is a lower threshold than in the Phase I study [20][39] Company Strategy and Development Direction - The company aims to differentiate its products in the market, particularly in the statin-sized market for cardiovascular treatments [10] - The focus is on advancing clinical programs across both proprietary and partnered pipelines, with expectations for strong execution in 2023 [27][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving key milestones by year-end, including top-line data from multiple ongoing studies [2][47] - There is a growing recognition of Lp(a) as a key cardiovascular risk factor, with increased awareness and testing among major societies [51] Other Important Information - The company has received FDA fast track and orphan drug designations for SLN124, indicating regulatory support for its development in rare diseases [33] - The company anticipates receiving up to $14 million in potential milestone payments from existing partnerships within the next 12 months [45] Q&A Session Summary Question: What kind of MACE reduction is needed for investor excitement regarding Lp(a)? - Management indicated that a 70% reduction in Lp(a) is generally needed to demonstrate therapeutic benefit, with current data showing higher reductions [37] Question: What insights are expected from the MAD portion of the Phase I trial? - The MAD portion will provide interim data that could optimize dosing for future studies, although it will not impact the ongoing Phase II trial [41] Question: What potential additional indications are being considered for SLN124? - Management noted that while both polycythemia vera and beta-thalassemia involve hepcidin, the underlying mechanisms differ, and they are exploring relevant indications for SLN124 [43]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Silence Therapeutics September 2022 Forward-Looking Statements The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any such restrictions ...